Haptoglobin Phenotype and Intensive Glycemic Control for Coronary Artery Disease Risk Reduction in People With Type 2 Diabetes: The ADVANCE Study
Diabetes Care · 01.05.2024 · 47 (5) · 835-843
DOI: 10.2337/dc23-2165 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes Care, online erschienen am 14.03.2024. Verfasst von Leah E Cahill und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Dalhousie University, Halifax, Canada. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Coronary Artery Disease, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NHLBI NIH HHS, CIHR.
Themen: Diabetes mellitus
Abstract (Originalsprache)
OBJECTIVE Intensive glycemic control reduced coronary artery disease (CAD) events among the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study participants with the haptoglobin (Hp)2-2 phenotype but not in participants without the Hp2-2 phenotype. It is unknown whether and how these results translate across different demographic/clinical characteristics and treatment strategies. RESEARCH DESIGN AND METHODS Haptoglobin phenotype was measured in available samples from the Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE) biomarker case-cohort study. Weighted multivariable-adjusted Cox regression models were used to evaluate the association between intensive glycemic control (HbA1c target of ≤6.5%) versus standard therapy (based on local guidelines) and major CAD events among participants with (n = 1,327) and without (n = 2,077) the Hp2-2 phenotype separately and within prespecified stratifications by sex, race, previous cardiovascular disease (CVD), diabetes duration, and HDL-cholesterol. RESULTS While the hazard ratios (HRs) were in the hypothesized differing directions, compared with standard therapy, intensive glycemic control was not significantly associated with risk of CAD events among participants without (1.04, 95% CI 0.82–1.32) or with (0.84, 0.63–1.14, Pinteraction = 0.27) the Hp2-2 phenotype overall. Intensive therapy was associated with lower CAD risk among participants with the Hp2-2 phenotype who had no previous CVD (0.47, 0.29–0.76, Pinteraction = 0.01). CONCLUSIONS Our findings suggest that intensive glycemic control contributes to the prevention of major CAD events among ADVANCE participants with the Hp2-2 phenotype and no previous CVD and are in alignment with our hypothesis that intensive glycemic control may be beneficial in a subset of people with the Hp2-2 phenotype.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Dalhousie University, Halifax, Canada.
- QEII Health Sciences Centre, Nova Scotia Health Authority, Halifax, Canada.
- Department of Community Health and Epidemiology, Dalhousie University, Halifax, Canada.
- Rappaport Faculty of Medicine, Technion Israel Institute of Technology, Haifa, Israel.
- Department of Medicine, Montreal Heart Institute, Université de Montréal, Montreal, Canada.
- Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.
ORCID-Profile: Leah E Cahill, Elizabeth Selvin, Michel Marre, Katie Harris, John Chalmers, Mark Woodward
Förderung
- NIDDK NIH HHS
- NHLBI NIH HHS
- CIHR
- Canadian Institutes of Health Research
Zitieren
APA
Cahill, L. E., Warren, R. A., Carew, A. S., Levy, A. P., Sapp, J., Samuel, M., Selvin, E., Lavallée, S. K., Poulter, N., Marre, M., Harrap, S., Mancia, G., Harris, K., Chalmers, J., Woodward, M., & Rimm, E. B. (2024). Haptoglobin Phenotype and Intensive Glycemic Control for Coronary Artery Disease Risk Reduction in People With Type 2 Diabetes: The ADVANCE Study. Diabetes Care, 47(5), 835-843. https://doi.org/10.2337/dc23-2165
Vancouver
Cahill LE, Warren RA, Carew AS, Levy AP, Sapp J, Samuel M, et al. Haptoglobin Phenotype and Intensive Glycemic Control for Coronary Artery Disease Risk Reduction in People With Type 2 Diabetes: The ADVANCE Study. Diabetes Care. 2024;47(5):835-843. doi:10.2337/dc23-2165
BibTeX
@article{Cahill2024,
author = {Cahill, Leah E and Warren, Rachel A and Carew, Allie S and Levy, Andrew P and Sapp, John and Samuel, Michelle and Selvin, Elizabeth and Lavallée, Samantha K and Poulter, Neil and Marre, Michel and Harrap, Stephen and Mancia, Giuseppe and Harris, Katie and Chalmers, John and Woodward, Mark and Rimm, Eric B},
title = {Haptoglobin Phenotype and Intensive Glycemic Control for Coronary Artery Disease Risk Reduction in People With Type 2 Diabetes: The ADVANCE Study},
journal = {Diabetes Care},
year = {2024},
volume = {47},
number = {5},
pages = {835--843},
doi = {10.2337/dc23-2165}
}
EUVIMED